ImaCor releases all-in-one platform for advanced hemodynamic management

Cutting Edge Technology Provides The Whole Picture In Critical Care

ImaCor, Inc, the developer of the world’s first and only hemodynamic transesophageal echocardiography (hTEE™) technology, today announced the release of its all-in-one platform for advanced hemodynamic management. Moreover, ImaCor has secured 510 (K) clearance from the U.S. Food and Drug Administration to market a transthoracic echocardiography (TTE) probe, making ImaCor’s platform the first-of-its-kind for hemodynamic management.

ImaCor’s all-in-one hemodynamic management platform is comprised of:

  • hTEE, enabled by the ClariTEE® probe that can be left indwelling for 72-hours and has been proven in multiple studies to change management in 66% of critical care patients;
  • hTTE™, a transthoracic probe for complementary hemodynamic management;
  • Hemodynamic trending, displaying cardiac filling and function data over time in a dashboard format;
  • Sizeable image quality improvements with 7 mHz resolution at 18 cm depth; and
  • Zura™ ultrasound systems, including the Zura EVO-1, the latest model in the Zura EVO™ family to offer new advanced processing for high definition imaging.

“I am impressed with the significant image quality improvements on ImaCor’s all-in-one hemodynamic management platform – it provides the whole picture in critical care,” said Nicholas Cavarocchi MD, FACS, FCCP, Director of the Surgical Critical Care Unit at Thomas Jefferson University Hospital. “Our time to stability with ImaCor’s technology has proven to be cutting edge.”

“We’ve had great success with our program for advanced hemodynamic management and witnessed the value that hTEE brings to our unit,” commented Robert N. Sladen MD, FCCM, Chief of the Division of Critical Care at Columbia University. “Given that hTEE is continuously available in our unit, having the ability to use hTTE will provide additional benefits to our program.”

“Strategically, our all-in-one hemodynamic management platform fulfills our vision of providing the most advanced technology in critical care,” explains Peter Pellerito, President & CEO of ImaCor Inc. “The new system delivers a higher level of capabilities to our customers, avoiding dramatic cost, while saving time, money, and ultimately, lives.”

Source: http://www.imacorinc.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds thousands of food-contact chemicals in humans, raising safety concerns